Revolution Medicines Inc.
Revolution Medicines Announces Q2 2024 Financial Results and Appoints New Director
Summary
Revolution Medicines, Inc. reported its Q2 2024 financial results on August 7, 2024, revealing a net loss of $133.2 million for the quarter and a cash position of $1.59 billion as of June 30, 2024. The company also appointed Frank K. Clyburn, Jr. to its Board of Directors, who brings extensive experience in the pharmaceutical industry, most recently from his role as CEO of International Flavors & Fragrances Inc. The company continues to advance its clinical programs for RAS(ON) inhibitors with plans to initiate pivotal trials for its RMC-6236 drug in pancreatic and lung cancers this year.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement